Methods： Between November 2022 and May 2024, patients with AIS within 24-72h of symptom onset and BP≥140/90 mmHg were enrolled and randomly assigned to receive Sacubitril/Valsartan (100-200mg qd) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback